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Available online 16 June 2016Hypertension (HTN) induced by bevacizumab is a side effect that is often thought to resolve after treatment.
However, there are currently no reports on rates of resolution. We assess the incidence and timing of the resolu-
tion of bevacizumab induced HTN.
We evaluated all patients treated with bevacizumab for gynecologic malignancies at a single institution from
2012 through 2014. HTN was retrospectively diagnosed and staged by CTCAE v4.0 criteria. Resolution of HTN
was deﬁned as ≥2 values return to baseline blood pressure and/or discontinuation/decrease of blood pressure
medications.
We identiﬁed 104 patients; 35were excluded due to receiving bevacizumab at time of analysis. Grade 2 or higher
induced HTNwas identiﬁed in 34/69 (49.3%) patients, of which 26/69 (37.7%) had grade 2 HTN and 8/69 (11.6%)
had grade 3/4 HTN. Onset of HTN occurred at amedian of 67 (14–791) days. Resolution of HTN occurred in 28/34
(82.4%) patients with a median time to resolution of 87 (3–236) days. BMI, history of HTN, blood pressure med-
ications, prior bevacizumab treatment, number of bevacizumab cycles, CA-125 and albumin at initiation of treat-
ment were not independent risk factors associatedwith developing HTN inmultivariate analysis. Median PFS for
those with HTN was 12.5 (1.9–45.8) months vs 11.0 (2.1–44.7) for those without (p = 0.17).
Hypertension induced by bevacizumab resolved in 82% of patients in a median of 87 days. There were no identi-
ﬁable risk factors associated with induced HTN and HTN was not a biomarker for improved prognosis in our
cohort.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Chemotherapy1. Introduction
Bevacizumab is a monoclonal antibody that targets vascular endo-
thelial growth factor (VEGF) and is approved by the US FDA for colorec-
tal cancer, renal cell cancer, glioblastoma, non-small cell lung cancer,
ovarian cancer and cervical cancer. Although FDA approval for gyneco-
logic malignancies was only obtained in 2014, Bevacizumab has been
utilized as an adjuvant or single agent chemotherapy for well over a
decade.
Hypertension (HTN) associated with the use of bevacizumab is one
of the most common side effects reported in the literature across onco-
logic ﬁelds. Meta-analyses have demonstrated overall incidence ofI GrantNumberUL1 RR025780.
ot necessarily represent ofﬁcial
logic Oncology, University of
e Campus Box B198-6, Aurora,
).
. This is an open access article underhypertension ranging from 2.7 to 32% and incidence of grade 3 or 4
HTN ranging from 1.8 to 22% (Ranpura et al., 2010). Incidence of grade
3 or 4 HTN when treating gynecologic malignancies ranges from 17–
25% (Burger et al., 2011; Perren et al., 2011; Aghajanian et al., 2012;
Tewari et al., 2014). If uncontrolled, hypertension can lead to many sig-
niﬁcant medical comorbidities such as heart disease, stroke, and kidney
disease.When hypertension is iatrogenically induced from cancer relat-
ed therapy, it is imperative for providers to understand, and report to
patients, the expected duration and risks.
The half-life of bevacizumab is estimated to be approximately
20 days (range 10–50 days) with doses of 1–20 mg/kg either weekly
or every three weeks (Syrigos et al., 2011). This infers that time to
drug clearance would be an estimated 100 days (5 half-lives). Time
analysis of onset and resolution of bevacizumab induced hypertension
is limited within the current literature. It is our hypothesis that hyper-
tensionwill resolvewith drug clearance of 100 days. The primary objec-
tive of this study was to identify the duration and rate of resolution for
bevacizumab induced hypertension. Secondary analysis were per-
formed to evaluate incidence of hypertension, identiﬁcation of riskthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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with induced hypertension compared to those without.
2. Methods and materials
All patients treated with bevacizumab for gynecologic malignancies
at a single institution from 2012 through 2014were reviewed. Approval
was obtained from the Institutional Review Board (IRB). Blood pressure
values were obtained and reviewed from all clinic visits prior to, during,
and post bevacizumab therapy. HTNwas diagnosed based on ≥2 record-
ed elevated blood pressure values in the medical record and staged by
Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
published by the National Institutes of Health and the National Cancer
Institute (Table 1). Resolution of HTN was deﬁned as ≥2 values of a re-
turn to baseline blood pressure and/or discontinuation/decrease of
blood pressuremedications. Patientswith preexistingHTNwere graded
with the same criteria andnoted as preexisting controlledHTN if ≤grade
1 HTN at time of presentation. Bevacizumab induced HTN was diag-
nosed in patients with preexisting HTN if there was an elevation of
grade by CTCAE criteria from their presenting pretreatment baseline
blood pressure. All demographic and clinical information was abstract-
ed from the medical chart. This information included age, BMI, malig-
nancy, history of HTN and/or blood pressure medication use,
bevacizumab treatment history, and presenting lab values of CA-125
and albumin. Baseline medical comorbidities were quantiﬁed using
the Charlson Comorbidity Index (CCI). The CCI is a validated instrument
used to estimate risk of death. It is a weighted index that assigns a score
based on medical comorbidities such as coronary artery disease, diabe-
tes, kidney or liver disease, ormetastatic solid tumors. All patient deaths
related to disease at time of analysis were noted and PFS was calculated
as length of time from initiation of bevacizumab treatment to docu-
mented date of disease progression or recurrence by radiography and/
or provider.
Study datawas collected andmanaged using the Research Electronic
Data Capture (REDCap). Descriptive statistics and tests of normality
were computed. Kolmogorov-Smirnov tests were used to assess nor-
mality of continuous variables. Non-normally distributed data were
compared using Mann-Whitney U tests. Continuous variables were
compared with Student’s t-tests. Dichotomous were compared usingTable 1
CTCAE v4.0 (U.S. Department of Health and Human Services, NIH, 2009.)
Grade
1
Mild; asymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention not
indicated.
Prehypertension (systolic BP
120–139 mm Hg or diastolic BP
80–89 mm Hg)
Grade
2
Moderate; minimal, local or
noninvasive intervention indicated;
limiting age-appropriate
instrumental activities of daily
living (ADL).
Stage 1 hypertension (systolic BP
140–159 mm Hg or diastolic BP
90–99 mm Hg); medical
intervention indicated; recurrent or
persistent (≥24 h); symptomatic
increase by N20 mm Hg (diastolic)
or to N140/90 mm Hg if previously
WNL; monotherapy indicated
Pediatric: recurrent or persistent
(≥24 h) BP N ULN; monotherapy
indicated
Grade
3
Severe or medically signiﬁcant but
not immediately life-threatening;
hospitalization or prolongation of
hospitalization indicated; disabling;
limiting self care ADL.
Stage 2 hypertension (systolic
BP≥160 mm Hg or diastolic BP≥100
mm Hg); medical intervention
indicated; more than one drug or
more intensive therapy than
previously used indicated
Grade
4
Life-threatening consequences;
urgent intervention indicated.
Life-threatening consequences
(e.g., malignant hypertension, tran-
sient or permanent neurologic
deﬁcit, hypertensive crisis); urgent
intervention indicated
Grade
5
Death related to adverse event. Deathchi-square or Fisher’s exact test for comparisons with cells b5. Kaplan-
Meierwas used to computemedian time to resolution of HTN and a sur-
vival curve. Statistical analysis was performed using IBM SPSS version
23.
3. Results
Of the 104patients identiﬁed, 35were excluded as theywere still re-
ceiving bevacizumab at the time of analysis. Patient characteristics are
presented in Table 2. Median follow-up time was 17.5 (2–50) months.
Overall incidence of ≥grade 2 bevacizumab induced hypertension was
49.3% (34/69). The majority of HTN requiring treatment was grade 2
with 26/69 (37.7%) and 8/69 (11.6%) patients had grade 3 or 4 (Table 3).
Median number of bevacizumab cycles in those with HTN was 11
(3–57) compared to 8 (1–49) in those without HTN (p= 0.09). Ninety
four percent (65/69) of patients received dosing of 15 mg/kg every
three weeks, six patients received 10 mg/kg every two weeks. Of
these six patients, 2 received dosing of 15mg/kg every threeweeks dur-
ing primary treatment and were reduced to 10 mg/kg every two weeks
formaintenance therapy, three patients received single agent treatment
of 10 mg/kg every two weeks for recurrent disease, and one patient re-
ceived 10 mg/kg every two weeks on trial.
Onset of HTN occurred at a median of 67 (14–791) days. Resolution
of HTN after the last dose of bevacizumab occurred in 28/34 (82.4%) pa-
tientswith amedian of 87 (3–236) days. Analysis of all patientswhode-
veloped HTN, including those who did not resolve in the study period,
demonstrates a median time to resolution of 104 days (Fig. 1). Of the
34 patients with bevacizumab induced HTN, 16/34 (46%) had an eleva-
tion of BP to ≥grade 2 HTNwho had a pre-existing diagnosis of ≥grade 2
HTN that was controlled on medications prior to initiation of
bevacizumab, compared to 14/35 (40%) patients who had an elevation
of BP to ≥grade 2 HTN who previously had no HTN or grade 1 HTN. In
patients requiring initiation of at least one new blood pressure medica-
tion, there was no consistency in type of medication started. Nine pa-
tients received diuretics, four β-blockers, seven angiotensin-
converting-enzyme inhibitors (ACE-I), two angiotensin II receptor
blockers (ARB), three calcium channel blockers (CCB), and one α-
blockers. Ten patients were either on a β-blocker prior to initiation of
bevacizumab or started on one during treatment. Median progression
free survival (PFS) for thosewithHTNwas 12.5 (1.9–45.8)months com-
pared to 11.0 (2.1–44.7) for those without HTN (p= 0.17). Median PFS
in patients with HTN on a β-blocker was 11.5 (4.0–21.9) months.Table 2
Characteristics of those with and without bevacizumab induced HTN.
HTN n=34 No HTN
n=35
p-value
Age (years; mean ± SD) 58.6 ± 11.6 57.3 ± 7.4 0.56
BMI (kg/m2; median (range)) 25.3
(19.7–46.4)
24.6
(17.5–125.0)
0.59
Malignancy 0.11
Ovary 32 (94.1%) 28 (80.0%)
Uterine 0 4 (11.4%)
Cervix 2 (5.9%) 3 (8.6%)
Hx of HTN 16 (47.1%) 14 (40.0%) 0.55
Prior BP medication use 13 (81.3%) 10 (71.4%) 0.53
Prior bevacizumab exposure 4 (11.8%) 5 (14.3%) 1.0
Number of bevacizumab cycles (median
(range))
11 ( 3–57) 8 (1–49) 0.09
CA-125a (median (range)) 358
(24–8107)
300
(12–6980)
0.48
Albuminb (g/dL; median (range)) 3.8 (2.9–4.5) 3.7 (2.8–4.5) 0.35
Charlson Comorbidity Index score
(median (range))
7.5 (0−12) 7 (2−10) 0.61
PFS (months; median (range)) 12.5
(1.9–45.8)
11.0
(2.1–44.7)
0.17
a CA-125 at initiation of bevacizumab treatment.
b Albumin at initiation of bevacizumab treatment.
Table 3
Induced hypertension as categorized by CTCAE v4.0
criteria.
n = 69 (%)
None 22 (31.9)
Grade 1 13 (18.8)
Grade 2 26 (37.7)
Grade 3 7 (10.1)
Grade 4 1 (1.5)
Grade 5 0
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bevacizumab treatment, number of bevacizumab cycles, CA-125 and al-
bumin at initiation of treatment, and the Charlson Comorbidity Index
were similar for the two groups in bivariate analyses (Table 2). The
number of bevacizumab cycles was slightly but not statistically signiﬁ-
cantly higher for those who develop HTN (median 11 vs. 8; p = 0.09).
No identiﬁable risk factor, of those evaluated, was identiﬁed for devel-
opment of induced HTN.
4. Discussion
This study demonstrates an incidence of ≥grade 2 bevacizumab in-
duced HTN of 49%, which is higher than the previously reported litera-
ture for gynecologic malignancies. In the AURELIA trial for platinum-
resistant recurrent ovarian cancer the incidence of grade 2 or higher hy-
pertensionwas 20%with the addition of bevacizumab to chemotherapy,
compared to 7% in the control arm (Pujade-Lauraine et al., 2014).
Tewari et al demonstrated an incidence of 25% grade 2 or higher hyper-
tension compared to 2% with the addition of bevacizumab in the treat-
ment of cervical cancer (Tewari et al., 2014). The OCEANS, ICON7 and
GOG218 trials incidence of grade 3 or 4 hypertension was 17%, 18%,
and 22.9% with the addition of bevacizumab, compared to 1%, 2%, and
7.2% in the control arms respectively (Burger et al., 2011; Perren et al.,
2011; Aghajanian et al., 2012). We demonstrate a rate of 11.6% of
grade 3 or 4 hypertension. We suspect that the increased incidence of
grade 2 HTN in this study is due to our retrospective analysis of HTN
being the primary outcome.We diagnosed HTN using CTCAE guidelines
(Table 1), analyzing all blood pressures in themedical chartwhether di-
agnosis was documented or not. While our criteria for HTN diagnosis is
identical to the Joint National Committee of prevention, detection, eval-
uation, and treatment of High blood pressure (JNC 7) (Moser, 2004), weFig. 1. Hypertension time to resolution curve Survival curve for time to resolution of all
patients who developed HTN on bevacizumab, including those who did not have
resolution of HTN within the time period studied.speculate that a retrospective analysis looking speciﬁcally at blood pres-
sure values over multiple visits would increase the diagnosis rate com-
pared to a prospective analysis looking at individual blood pressure
values, or ICD-9 codes for HTN.
Despite a high incidence of HTN, this study was unable to demon-
strate any associated risk factors associated with development of
bevacizumab induced HTN. We speciﬁcally analyzed age, BMI, history
of HTN, prior BP medication use, prior exposure to bevacizumab, CA-
125 values, albumin, and the Charlson comorbidity score (Table 2). Al-
thoughwe did not ﬁnd any risk factors associatedwith bevacizumab in-
duced HTN, the sample size was inadequate to detect a difference in
these secondary outcomes. Of note, number of cycles and PFS may be
slightly higher but did not reach statistical signiﬁcance. This contradicts
existing literature by Hamnvik et al. that demonstrated age, BMI, and
history of HTN as risk factors for anti-VEGF therapy induced HTN in
renal cell, hepatocellular, gastrointestinal, and sarcoma tumors
(Hamnvik et al., 2015). However, Hamnvik’s study looked at other
anti-VEGF therapies that did not include bevacizumab which may ac-
count for the variation in results. A separate established risk factor is
the dose of bevacizumab. Our study did not demonstrate dose to be an
associated risk factor, however 94% of our patients received 15 mg/kg
every three weeks and therefore this was not properly evaluated in
this study. This may be less relevant in treating gynecologic malignan-
cies as there is often little variation in dosing, as demonstrated in this
study.
The median time to onset of HTN in this study was 67 days. In rela-
tion to bevacizumab inducedHTN in renal cell carcinoma, Yang et al. de-
scribes median time to onset from ﬁrst dose as 131 days and states that
hypertension uniformly decreased after cessation of therapy for meta-
static renal cancer (Yang et al., 2003). Escalante et al. describe themedi-
an time to onset of hypertension in lung, breast and colorectal cancers
from ﬁrst dose as 7 days and post treatment decrease of hypertensive
medications as 30.5 days (11–162) (Escalante et al., 2013).
These trials, including ours, were relatively small cohorts that lack
consistency in malignancy treated as well as regimens used. These dif-
ferences may account for the discrepancy in time of onset.
In this study we demonstrate that 82% of bevacizumab induced
HTN resolved with a median of 87 days. This is consistent with the
pharmacokinetics of the drugs clearance, which would predict reso-
lution within 100 days. To understand resolution we must also un-
derstand the mechanism of action for its onset. The pathogenesis of
VEGF inhibitor induced hypertension has several potential mecha-
nisms and is likely multifactorial. Syrigos, et al. discusses the de-
creased nitric oxide synthesis leading to vasoconstriction, increased
vascular tone, and decreased sodium ion renal excretion. A decrease
in capillaries and arterioles due to VEGF inhibition will also increase
peripheral resistance. Furthermore, there may be an effect on renal
impairment by decreasing functionality between the podocytes and
endothelial cells of the kidney as demonstrated by proteinuria asso-
ciated with bevacizumab use (Ranpura et al., 2010; Syrigos et al.,
2011). It is unclear which of these mechanisms plays a majority roll
in this drug induced HTN, however a multifactorial etiology may ex-
plain why there is not complete resolution of HTN.
Grade 2 HTN is indication for intervention with medication. Of the
34 patients with ≥grade 2 HTN, 15 (44%) patients in our cohort were
started on a newmedication or medication added to their existing reg-
imen. There are currently noguidelines as to themost appropriate blood
pressure management for bevacizumab induced hypertension. This is
likely due to a multifactorial pathogenesis as well as a void in the
existing study of this subject. Our data indicates that the majority of
bevacizumab induced HTN is temporary. However, the JNC guidelines
do recommend treatment for grade 2 HTN and we suggest appropriate
adherence to these guidelines. Future studies should evaluate if strict
adherence to guidelines and tight blood pressure control during chemo-
therapy treatment has an impact on overall hypertension related mor-
bidity such as end organ damage, ischemia, or stroke.
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β-blocker therapy in patientswith ovarian cancer is associatedwith lon-
ger overall survival (OS) (Watkins et al., 2015).While our study did not
have signiﬁcant power to demonstrate beneﬁt in those with induced
HTN already on, or started on, a β-blocker it is an interesting inference
to consider β-blockade in those who develop bevacizumab induced
HTN. Currently there is no recommendation on which antihypertensive
therapy is the most appropriate for anti-VEGF induced HTN.
Given the high incidence of HTNwith anti-VEGF therapy and its po-
tentialmechanisms of action, it has been hypothesized that HTNmay be
amarker for drug efﬁcacy. Several studies have indicated that treatment
related hypertension can predict improved outcomes in renal cell, colo-
rectal and pancreatic cancers (Kindler et al., 2005; Osterlund et al.,
2011). Bono et al. found a PFS improvement of 4.1 months in patients
with renal cell cancer who had bevacizumab induced HTN compared
to thosewho did not (Bono et al., 2009). Our study did not demonstrate
a statistically signiﬁcant improvement in PFS in those who developed
bevacizumab induced HTN compared to those who did not. This re-
mains a relevant and interesting question that should be further evalu-
ated in larger trials.
Limitations of this study include its retrospective evaluation of a
small cohort at a single institution, analysis of heterogeneousmalignan-
cies and variation in dosing of bevacizumab. Poor compliance with ini-
tiation of treatment for grade 2 hypertension may also alter the time
to resolution, however we would not expect it to alter the incidence.
Further limitations are related to a lack of data in other potential con-
founding factors such as treatment of recurrent or primary disease,
combination of other chemotherapy regimens, race, urine protein/cre-
atinine and preexisting or induced renal pathology. Further studies are
warranted to evaluate risk factors for induced HTN, relation to associat-
ed hypertension related comorbidities, as well as effect on prognosis
within gynecologic malignancy. HTN is the most prevalent side effect
of bevacizumab in gynecologic malignancies. This paper is the ﬁrst to
demonstrate that themajority of bevacizumab induced HTN is transient
and resolves within the expected drug clearance timeframe.
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